Antiangiogenesis: The Fifth Cancer Treatment Modality?
Purpose/Objectives: To describe the biologic process of angiogenesis and the potential role of antiangiogenesis therapy in cancer treatment.
Data Sources: Published articles, conference proceedings, and computerized databases.
Data Synthesis: Angiogenesis is the development of blood vessels. Antiangiogenic agents prevent the development of blood vessels, therefore preventing one mode of cancer metastasis. Clinical trials must be conducted to ascertain the most powerful antiangiogenic therapies. Trials combine chemotherapy, biotherapy, and radiotherapy with antiangiogenic therapy.
Conclusions: Information from animal studies has revealed that antiangiogenesis is a viable option in treating cancer and preventing metastasis. Although human studies are rare, preliminary results are promising, especially when antiangiogenesis is used in combination with current cancer treatment modalities.
Implications for Nursing: Nurses are in a unique position to teach patients about new treatments for cancer. Nurses must be knowledgeable about angiogenesis and the availability of potential antiangiogenesis agents. Nurses will be vital in collecting data in clinical trials, considering the subjective data that will be obtained.
Jump to a section
References
Alexanian, R., & Weber, D. (2000). Thalidomide for resistant and relapsing myeloma. Seminars in Hematology, 37(1 Suppl. 3), 22-25.
Bagheri-Yarmand, R., Hamma-Kourbali, Y., Bissieres, P., Morere, J.F., & Crepin, M. (2001). Carboxymethyl benzylamide dextran and tamoxifen combination inhibits tumor growth and angiogenesis. Clinical Cancer Research, 7, 1805-1811.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M.R., Viale, G., et al. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clinical Cancer Research, 2, 1843-1849.
Brem, S., Brem, H., Folkman, J., Finkelstein, D., & Patz, A. (1976). Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Research, 36, 2807-2812.
Brouty-Boye, D., & Zetter, B.R. (1980). Inhibition of cell motility by inter-feron. Science, 208, 516-518.
Brown, J.M., & Giaccia, A.J. (1998). The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Research, 58, 1408-1416.
Cao, Y. (1999). Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica, 84, 643-650.
Cao, Y. (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. International Journal of Biochemistry and Cell Biology, 33, 357-369.
Carpizo, D., & Iruela-Arispe, M.L. (2000). Endogenous regulators of angiogenesis—Emphasis on proteins with thrombospondin—Type 1 motifs. Cancer and Metastasis Reviews, 19, 159-165.
Cascinu, S., Del Ferro, E., & Catalano, G. (1995). A randomised trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. British Journal of Cancer, 71, 97-101.
Compagni, A., Wilgenbus, P., Impagnatiello, M.A., Cotten, M., & Christofori, G. (2000). Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Research, 60, 7163-7169.
Eckhardt, S.G. (1999). Angiogenesis inhibitors as cancer therapy. Hospital Practice, 34(1), 63-68, 77-79, 83-84.
Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182-1186.
Folkman, J. (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New England Journal of Medicine, 333, 1757-1763.
Fontanini, G., Lucchi, M., Vignatti, S., Mussi, A., Ciardiello, F., De Laurentiis, M., et al. (1997). Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. Journal of the National Cancer Institute, 89, 881-886.
Fujisaki, K., Mitsuyama, K., Toyonaga, A., Matsuo, K., & Tanikawa, K. (1998). Circulating vascular endothelial growth factor in patients with colorectal cancer. American Journal of Gastroenterology, 93, 249-252.
Gately, S. (2000). The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastasis Reviews, 19, 19-27.
Gimbrone, M.A., Jr., Cotran, R.S., Leapman, S.B., & Folkman, J. (1974). Tumor growth and neovascularization: An experimental model using the rabbit cornea. Journal of the National Cancer Institute, 52, 413-427.
Gimbrone, M.A., Jr., Leapman, S.B., Cotran, R.S., & Folkman, J. (1972). Tumor dormancy in vivo by prevention of neovascularization. Journal of Experimental Medicine, 136, 261-276.
Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A., et al. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable form a fragment of thrombospondin. Proceedings of the National Academy of Sciences of the United States of America, 87, 6624-6628.
Gorski, D.H., Mauceri, H.J., Salloum, R.M., Gately, S., Hellman, S., Beckett, M.A., et al. (1998). Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Research, 58, 5686-5689.
Guyton, A.C. (1982). Human physiology and mechanisms of disease (3rd ed.). Philadelphia: Saunders.
Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
Harmey, J.H., Dimitriadis, E., Kay, E., Redmond, H.P., & Bouchier-Hayes, D.J. (1998). Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Annals of Surgical Oncology, 5, 271-278.
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., et al. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
Holmgren, L., O'Reilly, M.S., & Folkman, J. (1995). Dormancy of micro-metastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1, 149-153.
Jung, Y.D., Ahmad, S.A., Akagi, Y., Takahashi, Y., Liu, W., Reinmuth, N., et al. (2000). Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer and Metastasis Reviews, 19, 147-157.
Kaban, L.B., Mulliken, J.B., Ezekowitz, R.A., Ebb, D., Smith, P.S., & Folkman, J. (1999). Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics, 103(6 Pt. 1), 1145-1149.
Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., et al. (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-187.
Kudelka, A.P., Verschraegen, C.F., & Loyer, E. (1998). Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. New England Journal of Medicine, 338, 991-992.
Li, C.Y., Shan, S., Cao, Y., & Dewhirst, M.W. (2000). Role of incipient angiogenesis in cancer metastasis. Cancer and Metastasis Reviews, 19, 7-11.
Li, V.W., Folkerth, R.D., Watanabe, H., Yu, C., Rupnick, M., Barnes, P., et al. (1994). Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet, 344, 82-86.
Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S., Settle, S.L., Woerner, B.M., et al. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research, 60, 1306-1311.
McNamara, D.A., Harmey, J.H., Walsh, T.N., Redmond, H.P., & Bouchier-Hayes, D. (1998). Significance of angiogenesis in cancer therapy. British Journal of Surgery, 85, 1044-1055.
Miller, K.D., Sweeney, C.J., & Sledge, G.W., Jr. (2001). Redefining the target: Chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19, 1195-1206.
Nangia-Makker, P., Baccarini, S., & Raz, A. (2000). Carbohydrate-recognition and angiogenesis. Cancer and Metastasis Reviews, 19, 51-57.
Nesbit, M. (2000). Abrogation of tumor vasculature using gene therapy. Cancer and Metastasis Reviews, 19, 45-49.
O'Reilly, M.S., Holmgren, L., Chen, C., & Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine, 2, 689-692.
O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., et al. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
Paleolog, E.M., Young, S., Stark, A.C., McCloskey, R.V., Feldmann, M., & Maini, R.N. (1998). Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis and Rheumatism, 41, 1258-1265.
Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., et al. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 93, 2002-2007.
Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E., & Folkman, J. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. American Journal of Pathology, 150, 815-821.
Poon, R.T., Fan, S.T., & Wong, J. (2001). Clinical implications of circulating angiogenic factors in cancer patients. Journal of Clinical Oncology, 19, 1207-1225.
Pribluda, V.S., Gubish, E.R., Jr., LaVallee, T.M., Treston, A., Swartz, G.M., & Green, S.J. (2000). 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer and Metastasis Reviews, 19, 173-179.
Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., et al. (2000). Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proceedings, 75, 897-901.
Rastinejad, F., Polverini, P.J., & Bouck, N.P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56, 345-355.
Schirner, M. (2000). Antiangiogenic chemotherapeutic agents. Cancer and Metastasis Reviews, 19, 67-73.
Semenza, G.L. (2000). HIF-1: Using two hands to flip the angiogenic switch. Cancer and Metastasis Reviews, 19, 59-65.
Sheen-Chen, S.M., Chen, H.S., Sheen, C.W., Eng, H.L., & Chen, W.J. (2001). Serum levels of transforming growth factor betal in patients with breast cancer. Archives of Surgery, 136, 937-940.
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
Sliutz, G., Tempfer, C., Obermair, A., Reinthaller, A., Gitsch, G., & Kainz, C. (1995). Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Letters, 94, 227-231.
Soff, G.A. (2000). Angiostatin and angiostatin-related proteins. Cancer and Metastasis Reviews, 19, 97-107.
Stirling, D.I. (2000). Pharmacology of thalidomide. Seminars in Hematology, 37(Suppl. 3), 5-14.
Taylor, S., & Folkman, J. (1982). Protamine is an inhibitor of angiogenesis. Nature, 297, 307-312.
Vacca, A., Iurlaro, M., Ribatti, D., Minischetti, M., Nico, B., Ria, R., et al. (1999). Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood, 94, 4143-4155.
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., et al. (1994). Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
van Eys, J. (1987). Living beyond cure. Transcending survival. American Journal of Pediatric Hematology/Oncology, 9, 114-118.
Varda-Bloom, N., Shaish, A., Gonen, A., Levanon, K., Greenbereger, S., Ferber, S., et al. (2001). Tissue-specific gene therapy directed to tumor angiogenesis. Gene Therapy, 8, 819-827.
Volpert, O.V. (2000). Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: A dynamic balance. Cancer and Metastasis Reviews, 19, 87-92.
Weidner, N., Semple, J.P., Welch, W.R., & Folkman, J. (1991). Tumor angiogenesis and metastasis—Correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1-8.
Yamamoto, S., Konishi, I., Mandai, M., Kuroda, H., Komatsu, T., Nanbu, K., et al. (1997). Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British Journal of Cancer, 76, 1221-1227.